A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Fluticasone propionate (Primary) ; Salmeterol/fluticasone propionate (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 18 Mar 2020 Primary endpoint (For FS MDPI versus Fp MDPI: the change from baseline in 1-hour postdose percent predicted morning FEV1 at week 12) has not been met as per results published in the ClinicalTrials.gov Trial Registry
- 18 Mar 2020 Primary endpoint (For Fp MDPI versus placebo: the change from baseline in weekly average of the percent predicted trough morning forced expiratory volume in 1 second (FEV1) at week 12) has been met as per results published in the ClinicalTrials.gov Trial Registry
- 18 Mar 2020 Results published in the ClinicalTrials.gov Trial Registry